KRAS degradation averts PDAC chemoresistance

Nat Cancer. 2024 Mar;5(3):375-377. doi: 10.1038/s43018-023-00708-7.

Laura Leonhardt^{1

2

3}, Matthias Hebrok^{4

5

6

7

8

9}

¹ TUM School of Medicine and Health, Technical University Munich, Munich, Germany.
² Center for Organoid Systems, Technical University Munich, Garching, Germany.
³ Institute for Diabetes and Organoid Technology, Helmholtz Diabetes Center, Helmholtz Zentrum München, Neuherberg, Germany.
⁴ TUM School of Medicine and Health, Technical University Munich, Munich, Germany. matthias.hebrok@tum.de.
⁵ Center for Organoid Systems, Technical University Munich, Garching, Germany. matthias.hebrok@tum.de.
⁶ Institute for Diabetes and Organoid Technology, Helmholtz Diabetes Center, Helmholtz Zentrum München, Neuherberg, Germany. matthias.hebrok@tum.de.
⁷ Munich Institute of Biomedical Engineering (MIBE), Technical University Munich, Munich, Germany. matthias.hebrok@tum.de.
⁸ German Center for Diabetes Research (DZD), Neuherberg, Germany. matthias.hebrok@tum.de.
⁹ Diabetes Center, Department of Medicine, University of California San Francisco, San Francisco, CA, USA. matthias.hebrok@tum.de.

No abstract available

MeSH terms